CD274 and neoplasm: Finally, results from the SAFIR02-BREAST IMMUNO study showed that, among patients with metastatic TNBC durvalumab versus maintenance therapy, there was no association between OS and tumor infiltration by lymphocytes, although there was an association between OS and CD274 amplification/gain and efficacy22.